FIELD: medicine.
SUBSTANCE: group of inventions refers to treatment of malignant disease. Composition for treating a malignant disease comprises an effective amount of pertuzumab and a variant thereof with unpaired cysteines, wherein said version with unpaired cysteines contains Cys23 and Cys88 in both variable domains of light chain of pertuzumab and Cys23/Cys88 unpaired cysteines in one or both variable domains of its light chain. Also disclosed are a pharmaceutical composition for treating a malignant disease, an article for treating a malignant disease, an isolated version of pertuzumab for treating a malignant disease and another version of the composition for treating a malignant disease.
EFFECT: group of inventions widens range of means for certain purposes.
15 cl, 45 dwg, 19 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HER2 ANTIBODY DRUGS FOR SUBCUTANEOUS INJECTION | 2018 |
|
RU2750821C2 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
| METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR TREATING BILE DUCT CANCER | 2019 |
|
RU2819802C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
